Linezolid Toxicity in South African Children With Rifampicin-resistant Tuberculosis.

Area of Science:

• Pediatric infectious diseases
• Pharmacovigilance in children
• Antimicrobial resistance management

Background:

• Limited data exists on linezolid toxicity in pediatric drug-resistant tuberculosis (DR-TB).
• Understanding adverse events is crucial for safe and effective pediatric DR-TB treatment.
• South African children represent a vulnerable population for TB treatment outcomes.

Purpose of the Study:

• To investigate the incidence and characteristics of linezolid-attributed toxicity in South African children with DR-TB.
• To identify risk factors and timing of adverse events associated with linezolid use.
• To inform clinical management guidelines for pediatric DR-TB.

Main Methods:

• Prospective cohort study design.
• Inclusion of South African children undergoing linezolid treatment for DR-TB.
• Systematic monitoring and recording of adverse events, including anemia, thrombocytopenia, and peripheral neuropathy.

Main Results:

• Anemia, thrombocytopenia, and peripheral neuropathy were frequently observed in children treated with linezolid.
• These adverse events were often severe and necessitated active clinical management.
• Peripheral neuropathy and grade 3/4 events typically manifested after a treatment duration of three months or longer.

Conclusions:

• Linezolid treatment in children with DR-TB is associated with a high burden of toxicity.
• Early recognition and management of linezolid-induced adverse events are critical for pediatric patient care.
• Further research is needed to optimize linezolid dosing and duration in pediatric DR-TB.